More on mini-gastric bypass.

S. Olchowski,M. Timms,P. O'Brien,R. Bauman,J. K. Quattlebaum

Obesity Surgery

Abstract:

What problem does this paper attempt to address?

The Cannabis and Health Research Initiative will help integrate medicinal cannabis in healthcare

Johannes Thrul,Ryan Vandrey

DOI: https://doi.org/10.1038/s41591-024-03288-w

IF: 82.9

2024-10-23

Nature Medicine

Abstract:In the USA, there are more than 5.5 million registered patients in state-regulated medicinal cannabis programs and many people use hemp products (sourced from cannabis containing <0.3% delta-9-tetrahydrocannabinol (THC) by dry weight) for therapeutic purposes. However, clinical research on non-pharmaceutical cannabis products remains limited 1 , healthcare providers feel inadequately trained on integrating medicinal cannabis into their practice 2 , and medicinal cannabis use is poorly documented in electronic medical records (EMRs) 3 . These issues highlight the need for patient-level data on the impacts of medicinal cannabis use 4 . With legalization of retail cannabis sales in some US states, the diversity of cannabis products available to consumers has substantially increased 5 . Products vary in chemical composition 6 , dose and intended route of administration, all of which can affect clinical effect, safety and abuse liability, and should be considered in clinical decision making. The diversity in cannabis products and the use of poorly defined nomenclature contributes to difficulty in assessing the health effects of medicinal cannabis.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Patient–provider interactions about cannabis for therapeutic purposes vary as a function of provider type: A pilot study

Jivan Achar,Alan J. Budney,Cara A. Struble

DOI: https://doi.org/10.1111/ajad.13656

2024-10-26

American Journal on Addictions

Abstract:Background and Objectives Limited evidence guides the efficacy and safety of cannabis for therapeutic purposes (CTP). Healthcare providers lack requisite knowledge to advise and support patients. This study aimed to describe and compare several aspects of initial CTP interactions across different provider types. Methods Adult cannabis consumers (N = 507) from the United States completed an anonymous online survey about their initial CTP interaction with their healthcare provider. Providers were categorized into four groups (Mental Health [MH], Family Medicine [FM], Medical Clinics [MC], and Other Specialty [OS]). Analyses compared several aspects of the interaction (e.g., risk mitigation, recommendations, satisfaction/confidence) across groups. Results Less than half of the sample reported discussion of cannabis risks (44.0%) or follow‐ups at subsequent visits (46.7%). Recommendations (where to obtain, consumption method, dose, frequency, and authorization) were uncommon (9.7%–25.2%). While the MH group reported the highest rates of risk mitigation behaviors, regression models adjusted for sociodemographic and cannabis characteristics were largely nonsignificant. For recommendations, the MC group was more likely than the MH group to report receiving all recommendations (p

substance abuse
State of the Science: Health Care Provider Communication of Cannabis Use Among Adults Living with Cancer

Amrit Baral,Bria-Necole A. Diggs,Judith Greengold,Cynthia Foronda,Debbie Anglade,Marlene Camacho-Rivera,Jessica Y. Islam,Denise C. Vidot

DOI: https://doi.org/10.1007/s13187-024-02484-z

2024-08-21

Journal of Cancer Education

Abstract:Despite medicinal cannabis gaining popularity for managing symptoms in cancer patients, a knowledge gap exists in patient-provider communication crucial for monitoring outcomes, optimizing dosing, and educating healthcare providers to integrate cannabis into treatment plans. Our goal is to understand communication dynamics, identify gaps, and pave the way for effective cannabis communication for individuals living with cancer (PLWC). We searched PubMed, CINAHL, and EBSCO for articles published between 2013 and July 2023, capturing the key concepts of cannabis use in cancer patients and their communication with healthcare providers in oncology settings. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guided the review. Studies were appraised by applying the Johns Hopkins Evidence-Based Practice Model for Nursing and Healthcare Professionals. Of the 2384 articles reviewed, 14 met the inclusion criteria. Three were qualitative studies, and 11 were cross-sectional surveys. All studies were level III evidence. Studies captured patients' and providers' perspectives; five were conducted among cancer patients, and nine were among healthcare providers in oncology settings. Findings revealed variations in healthcare provider recommendations, patient-initiated discussions, and barriers to discussing medical cannabis (MC). The synthesis of this evidence highlights the complexities surrounding MC in oncology settings, including knowledge gaps among healthcare providers, patient-initiated discussions, and challenges in accessing and prescribing medicinal cannabis. This review contributes valuable insights into the current landscape of MC use in cancer care, emphasizing the need for improved communication, education, and support for both patients and healthcare providers.

oncology,public, environmental & occupational health,education, scientific disciplines
Planting the seeds for success: A qualitative study exploring primary healthcare providers’ perceptions about medical cannabis

Sandi Schuhmacher,Dina Gaid,Lisa D. Bishop,Laura Fleming,Jennifer Donnan

DOI: https://doi.org/10.1371/journal.pone.0295858

IF: 3.7

2024-03-07

PLoS ONE

Abstract:Background In Canada, cannabis legalization altered the way that the public can access cannabis for medical purposes. However, Canadians still struggle with finding healthcare professionals (HCPs) who are involved in medical cannabis counselling and authorization. This raises questions about the barriers that are causing this breakdown in care. Our study explored the perceptions of primary care providers regarding cannabis in their practice. Methods Semi-structured interviews were conducted by Zoom with HCPs in Newfoundland and Labrador (NL) to discuss their experiences with medical and non-medical cannabis in practice. Family physicians and nurse practitioners who were practicing in primary care in NL were included. The interview guide and coding template were developed using the Theoretical Domains Framework (TDF). A thematic analysis across the TDF was then conducted. Results Twelve participants with diverse demographic backgrounds and experience levels were interviewed. Five main themes emerged including, knowledge acquisition, internal influences, patient influences, external HCP influences, and systemic influences. The TDF domain resulting in the greatest representation of codes was environmental context and resources. Interpretation The findings suggested that HCPs have significant knowledge gaps in authorizing medical cannabis, which limited their practice competence and confidence in this area. Referring patients to cannabis clinics, while enforcing harm-reduction strategies, was an interim option for patients to access cannabis for medical purposes. However, developing practice guidelines and educational resources were suggested as prominent facilitators to promote medical cannabis authorization within the healthcare system.

multidisciplinary sciences
Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues

Ethan B. Russo

DOI: https://doi.org/10.3389/fphar.2016.00309

IF: 5.6

2016-09-14

Frontiers in Pharmacology

Abstract:This overview covers a wide range of cannabis topics, initially examining issues in dispensaries and self-administration, plus regulatory requirements for production of cannabis-based medicines, particularly the Food and Drug Administration "Botanical Guidance." The remainder pertains to various cannabis controversies that certainly require closer examination if the scientific, consumer, and governmental stakeholders are ever to reach consensus on safety issues, specifically: whether botanical cannabis displays herbal synergy of its components, pharmacokinetics of cannabis and dose titration, whether cannabis medicines produce cyclo-oxygenase inhibition, cannabis-drug interactions, and cytochrome P450 issues, whether cannabis randomized clinical trials are properly blinded, combatting the placebo effect in those trials via new approaches, the drug abuse liability (DAL) of cannabis-based medicines and their regulatory scheduling, their effects on cognitive function and psychiatric sequelae, immunological effects, cannabis and driving safety, youth usage, issues related to cannabis smoking and vaporization, cannabis concentrates and vape-pens, and laboratory analysis for contamination with bacteria and heavy metals. Finally, the issue of pesticide usage on cannabis crops is addressed. New and disturbing data on pesticide residues in legal cannabis products in Washington State are presented with the observation of an 84.6% contamination rate including potentially neurotoxic and carcinogenic agents. With ongoing developments in legalization of cannabis in medical and recreational settings, numerous scientific, safety, and public health issues remain.

pharmacology & pharmacy
Palliative Medicine Fellows’ Discussions, Perceptions, and Training Regarding Medical Cannabis

Dylan R Sherry,Rushad Patell,Harry J Han,Laura E Dodge,Ilana M Braun,Mary K Buss,Dylan R. Sherry,Harry J. Han,Laura E. Dodge,Ilana M. Braun,Mary K. Buss

DOI: https://doi.org/10.1016/j.jpainsymman.2024.02.562

IF: 5.576

2024-02-01

Journal of Pain and Symptom Management

Abstract:CONTEXT: Medical cannabis is increasingly considered for palliation of pain, nausea/vomiting, anorexia, and other symptoms.OBJECTIVES: We aimed to determine whether training in hospice and palliative medicine (HPM) adequately prepares fellows to counsel patients about medical cannabis.METHODS: A previously validated questionnaire was adapted for HPM fellows. Domains included fellows' practices recommending cannabis and their knowledge of its effectiveness and risks compared with standard treatments. U.S. HPM fellowships were sent surveys in 2022 and 2023.RESULTS: Forty six programs participated, 123 fellows responded (response rate of 42%) including 69% female; 55% White, and 28% Asian. Of respondents, 65% reported receiving formal training regarding medical cannabis; 57% reported discussing medical cannabis with over five patients; 23% recommended medical cannabis to more than five patients in the preceding year. Only 19%, however, felt sufficiently informed to issue cannabis-related recommendations. HPM fellows with prior training were not more likely to feel sufficiently informed to discuss cannabis (RR: 1.17; 95% CI: 0.82-1.66) or to recommend cannabis to patients (RR: 2.05, 95% CI: 0.89-4.71). Fellows rate cannabis as equally or more effective than conventional treatments for the following symptoms: anorexia/cachexia (63%), nausea/vomiting (43%), pain (25%), and neuropathic pain (21%).CONCLUSION: Most HPM fellows report formal training in the use of medical cannabis. Over half of trainees reported discussing medical cannabis with patients, but few considered themselves sufficiently informed to make cannabis-related clinical recommendations. These results suggest both a need for expanded high-quality evidence for medical cannabis in palliative care and for improved formal education for HPM fellows.

medicine, general & internal,clinical neurology,health care sciences & services
VA Providers' Perceptions of Cannabis Use Policies in a Legalized and Nonlegalized State

Julie Bobitt,Kelsey Berryman,Frances M Weaver

DOI: https://doi.org/10.1089/can.2023.0276

2024-04-08

Abstract:Background: Providers in the Department of Veterans Affairs (VA) system are caught between two opposing sets of laws regarding cannabis and cannabidiol (CBD) use by their patients. As VA is a federal agency, it must abide by federal regulations, including that the Food and Drug Administration classifies cannabis as a Schedule 1 drug and therefore cannot recommend or help Veterans obtain it. Meanwhile, 38 states have passed legislation, legalizing medical use of cannabis. Objective: The goal of this project is to examine how VA providers understand state and federal laws, and VA policies about cannabis and CBD use, and to learn more about providers' experiences with patients who use cannabis and CBD within a legalized and nonlegalized state. Materials and Methods: We identified 432 health care providers from two VA facilities in northern Illinois (IL) where medical and recreational cannabis is legal, and two VA facilities in southern Wisconsin (WI) where medical and recreational cannabis is illegal. Participants were invited via e-mail to complete an anonymous online survey, including 31 closed- and open-ended questions about knowledge of state and federal laws and VA policies regarding cannabis and CBD oil, thoughts about the value of cannabis or CBD for treating medical conditions, and behaviors regarding cannabis use by their patients. Results: We received 50 responses (IL N=20, WI N=30). Providers in both states were knowledgeable about cannabis laws in their state but unsure whether they could recommend cannabis. There were more providers who were unclear if they could have a conversation about cannabis with their VA patients in WI compared with IL. Providers were more likely to agree than disagree that cannabis can be beneficial, χ2 (1, 49)=4.74, p=0.030. Providers in both states (81.6%) believe cannabis use is acceptable for end-of-life care, but responses varied for other conditions and symptoms. Discussion: Findings suggest that VA providers could use more guidance on what is allowable within their VA facilities and how state laws affect their practice. Education about safety related to cannabis and other drug interactions would be helpful. There is limited information about possible interactions, warranting future research.
Early promising outcome following arthroscopic implantation of the subacromial balloon spacer for treating massive rotator cuff tear

R. S. M. Piekaar,I. C. E. Bouman,P. M. van Kampen,F. van Eijk,P. Huijsmans

DOI: https://doi.org/10.1007/s12306-017-0525-5

2018-12-01

MUSCULOSKELETAL SURGERY

Abstract:
Cannabis Use in Parkinson's Disease: Patient Access to Medical Cannabis and Physician Perspective on Product Safety

Symone T. Griffith,Kendra D. Conrow,Michael Go,Mindy L. McEntee,Raminta Daniulaityte,Majia H. Nadesan,Mathew R. Swinburne,Holly A. Shill,Maxwell C.K. Leung

DOI: https://doi.org/10.1016/j.neuro.2024.05.008

IF: 4.398

2024-06-05

NeuroToxicology

Abstract:The rate of medical cannabis use has increased in parallel with the number of states legalizing its use. Parkinson's disease (PD) patients are of particular concern due to their higher cannabis use rate than in the general US population (25-40% PD patient cannabis users vs. ~18% in the general population), as well as their susceptibility to environmental contaminants in cannabis, including pesticides, toxic elements, solvents, microbes, and mycotoxins. In order to address the complex nature of this industry, we examined the changes in PD-related qualifying conditions in the U.S. from 2019 to 2023. We also conducted an online survey to gain insight into the knowledge, risk perceptions, and opinions regarding medical cannabis and contamination issues from physicians who treated PD patients. The number of states including PD-related qualifying conditions increased over the past 5 years from 28 to 36 states. These conditions included PD (increasing from 14 to 16 states), muscle spasms (14 to 24), anxiety (1 to 5), and pain (17 to 35). State-by-state comparisons revealed high variability in the language used to describe the different qualifying conditions. Online surveys were sent out to 45 neurologists and movement disorder specialists who primarily treated PD patients. The response rate was 44% from nine states (AZ, CA, FL, MA, MN, WI, PA, IL, and NM). When asked if they were aware of any contaminants in cannabis products, we found that 65% of the physicians were unaware of any contaminants commonly found in cannabis and only 25%, 15%, and 15% of them were aware of pesticide, toxic element, and solvent contaminants, respectively. In their free-text opinion response on the health impact of cannabis-borne contaminants, "long-term effect" (35%) and "comorbidities and PD prognosis" (40%) were identified as the two most common themes. These results point to the need for further regulatory deliberation regarding risks and susceptibility to cannabis contaminants. Additionally, education is needed to inform physicians on cannabis safety issues. Further research will identify the implementation strategies to reduce contaminant exposure and protect patient health.

pharmacology & pharmacy,neurosciences,toxicology
Analysis of State Cannabis Laws and Dispensary Staff Recommendations to Adults Purchasing Medical Cannabis

Jessica S. Merlin,Andrew Althouse,Robert Feldman,Julia H. Arnsten,Hailey W. Bulls,Jane M. Liebschutz,Shannon M. Nugent,Steven R. Orris,Rebecca Rohac,Joanna L. Starrels,Benjamin J. Morasco,Devan Kansagara

DOI: https://doi.org/10.1001/jamanetworkopen.2021.24511

2021-09-15

JAMA Network Open

Abstract:Importance: Over the last decade, cannabis has become more accessible through the proliferation of dispensaries in states that have legalized its use. Most patients using cannabis for medical purposes report getting advice from dispensaries, yet there has been little exploration of frontline dispensary staff practices.Objective: To describe the practices of frontline dispensary workers who interact with customers purchasing cannabis for medical purposes and assess whether dispensary practices are associated with medicalization of state cannabis laws (degree to which they resemble regulation of prescription or over-the-counter drugs) and statewide adult use.Design, Setting, and Participants: This nationwide cross-sectional survey study was conducted from February 13, 2020, to October 2, 2020, using an online survey tool. Potential respondents were eligible if they reported working in a dispensary that sells tetrahydrocannabinol-containing products and interacting with customers about cannabis purchases.Main Outcomes and Measures: Participant responses to questions about formulating customer recommendations and talking to customers about risks.Results: The 434 survey responses from 351 unique dispensaries were most often completed by individuals who identified as budtenders (40%), managers (32%), and pharmacists (13%). Most respondents reported basing customer recommendations on the customer's medical condition (74%), the experiences of other customers (70%), the customer's prior experience with cannabis (67%), and the respondent's personal experience (63%); fewer respondents relied on clinician input (40%), cost (45%), or inventory (12%). Most respondents routinely advised customers about safe storage and common adverse effects, but few counseled customers about cannabis use disorder, withdrawal, motor vehicle collision risk, or psychotic reactions. A higher state medicalization score was significantly associated with using employer training (odds ratio, 1.41; 95% CI, 1.18-1.67) and physician or clinician input (odds ratio, 1.23; 95% CI, 1.05-1.43) as a basis for recommendation. Medicalization score was not associated with counseling about cannabis risks.Conclusions and Relevance: This survey study provides insight into how frontline dispensary staff base cannabis recommendations and counsel about risks. The findings may have utility for clinicians to counsel patients who purchase cannabis, customers who want to be prepared for a dispensary visit, and policy makers whose decisions affect cannabis laws.

medicine, general & internal
The evolving culture of medical cannabis in Canada for the management of chronic pain

H Clarke,M Fitzcharles

DOI: https://doi.org/10.3389/fphar.2023.1153584

2023-04-07

Abstract:Although used therapeutically for millennia, cannabis has been a prohibited substance worldwide for most of the 20th Century. With revision of prohibitive regulations in many jurisdictions during the past 2 decades, cannabis is increasingly available to patients as a potential treatment option for various symptoms. Pain relief, sleep promotion and alleviation of distress, depression and anxiety are the most common reasons for cannabis use. Canada has been at the forefront of medical cannabis (MC) legislation revisions to enable and facilitate access for therapeutic use. Although initially viewed with caution and stigma, attitudes to cannabis in general have changed. Medical cannabis is identified as the herbal plant product sourced from a grower/producer and is not at present a regulated pharmaceutical product. Medical cannabis use is currently prevalent in Canada but has bypassed the rigorous study required for usual drug approval. Although uptake has been enthusiastic by patients, the medical community has voiced cautions and concerns. Access to medical cannabis is fairly easy once an approval document is obtained from a healthcare professional, but without obligation for medical or pharmacy oversight. The greatest concern is a dearth of sound clinical evidence for effects and harms. Emerging concerns include prevalent patient self-management with information based on personal research, an abundance of on-line information which may not always be accurate, the emergence of designated "cannabis clinics," potential risks to society due to accidents, and high cost of the legal medical product leading to access via the recreational market. With cannabis now entrenched in Canadian healthcare, physicians must be sufficiently knowledgeable to provide guidance that is evidence-based and will ensure personal and societal harm reduction. Examination of the changing culture of medical cannabis in Canada will provide insight for countries that may be anticipating similar revisions of cannabis regulations to allow cannabis access for their patient population and learn from the issues created by recreational legalization.
Response competition effects insame-different judgments

C. W. Eriksen,William P. O’hara,B. Eriksen

DOI: https://doi.org/10.3758/BF03206230

1982-05-01

Perception & Psychophysics

Abstract:
Cannabis dispensary staff approaches to counseling on potential contraindications to cannabis use: insights from a national self-report survey

Deepika E. Slawek,Andrew D. Althouse,Robert Feldman,Julia H. Arnsten,Hailey W. Bulls,Jane M. Liebschutz,Shannon M. Nugent,Steven R. Orris,Rebecca Rohac,Joanna L. Starrels,Benjamin J. Morasco,Devan Kansagara,Jessica S. Merlin

DOI: https://doi.org/10.1186/s12875-023-02095-5

2023-07-14

BMC Primary Care

Abstract:Legal cannabis is available in more than half of the United States. Health care professionals (HCPs) rarely give recommendations on dosing or safety of cannabis due to limits imposed by policy and lack of knowledge. Customer-facing cannabis dispensary staff, including clinicians (pharmacists, nurses, physician's assistants), communicate these recommendations in the absence of HCP recommendations. Little is known about how dispensary staff approach individuals with complex medical and psychiatric comorbidities. Using responses from a national survey, we describe how cannabis dispensary staff counsel customers with medical and psychiatric comorbidities on cannabis use and examine whether state-specific cannabis policy is associated with advice given to customers.
On Solving Lq-Penalized Regressions

T. Z. Wu,Yingyi Chu,Yan Yu

DOI: https://doi.org/10.1155/2007/24053

2007-10-30

Advances in Decision Sciences

Abstract:L q -penalized regression arises in multidimensional statistical modelling where all or part of the regression coefficients are penalized to achieve both accuracy and parsimony of statistical models. There is often substantial computational difficulty except for the quadratic penalty case. The difficulty is partly due to the nonsmoothness of the objective function inherited from the use of the absolute value. We propose a new solution method for the general L q -penalized regression problem based on space transformation and thus efficient optimization algorithms. The new method has immediate applications in statistics, notably in penalized spline smoothing problems. In particular, the LASSO problem is shown to be polynomial time solvable. Numerical studies show promise of our approach.
Medical cannabis in schools: A qualitative study on the experiences of clinicians

Holly Mansell,Zina Zaslawski,Lauren E Kelly,Taylor Lougheed,Tracy Brace,Jane Alcorn

DOI: https://doi.org/10.1093/pch/pxac110

2022-11-12

Abstract:Objectives: Guidance is lacking for medical cannabis use in Canadian schools in both legislation and approach; the impact of ambiguous policy on patient care is unknown. A qualitative study was undertaken to explore the experiences of clinicians who care for school-aged children who take medical cannabis. Methods: Semi-structured interviews were recorded and transcribed verbatim. Qualitative content analysis performed using the Dedoose qualitative software ascribed meaning units and codes, which were further consolidated into categories and subcategories. Results: Thirteen physicians were interviewed virtually, representing seven provinces in Canada. The physicians provided care for between five and hundreds of school-aged children who took medical cannabis. The most common indications were refractory seizure disorders and autism. The interviews provided rich descriptions on perceptions of medical cannabis in schools, and in general. Five overarching categories were identified across both domains including variability, challenges (subcategories: lack of knowledge, stigma, lack of policy, and pragmatic challenges), potential solutions (subcategories: treat it like other medications, communication, education, and family support), positive experiences and improvements over time. Conclusion: In Canada, cannabis-based medicine use in schools still faces important challenges. Effective education, communication, family support and policy refinements that allow cannabis to be treated like other prescription medications are recommended to improve the status quo. These findings will guide the C4T Medical Cannabis in Schools Working Group's future priorities and initiatives.
Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process

Arun Bhaskar,Alan Bell,Michael Boivin,Wellington Briques,Matthew Brown,Hance Clarke,Claude Cyr,Elon Eisenberg,Ricardo Ferreira de Oliveira Silva,Eva Frohlich,Peter Georgius,Malcolm Hogg,Tina Ingrid Horsted,Caroline A. MacCallum,Kirsten R. Müller-Vahl,Colleen O’Connell,Robert Sealey,Marc Seibolt,Aaron Sihota,Brennan K. Smith,Dustin Sulak,Antonio Vigano,Dwight E. Moulin

DOI: https://doi.org/10.1186/s42238-021-00073-1

2021-07-02

Journal of Cannabis Research

Abstract:Abstract Background Globally, medical cannabis legalization has increased in recent years and medical cannabis is commonly used to treat chronic pain. However, there are few randomized control trials studying medical cannabis indicating expert guidance on how to dose and administer medical cannabis safely and effectively is needed. Methods Using a multistage modified Delphi process, twenty global experts across nine countries developed consensus-based recommendations on how to dose and administer medical cannabis in patients with chronic pain. Results There was consensus that medical cannabis may be considered for patients experiencing neuropathic, inflammatory, nociplastic, and mixed pain. Three treatment protocols were developed. A routine protocol where the clinician initiates the patient on a CBD-predominant variety at a dose of 5 mg CBD twice daily and titrates the CBD-predominant dose by 10 mg every 2 to 3 days until the patient reaches their goals, or up to 40 mg/day. At a CBD-predominant dose of 40 mg/day, clinicians may consider adding THC at 2.5 mg and titrate by 2.5 mg every 2 to 7 days until a maximum daily dose of 40 mg/day of THC. A conservative protocol where the clinician initiates the patient on a CBD-predominant variety at a dose of 5 mg once daily and titrates the CBD-predominant dose by 10 mg every 2 to 3 days until the patient reaches their goals, or up to 40 mg/day. At a CBD-predominant dose of 40 mg/day, clinicians may consider adding THC at 1 mg/day and titrate by 1 mg every 7 days until a maximum daily dose of 40 mg/day of THC. A rapid protocol where the clinician initiates the patient on a balanced THC:CBD variety at 2.5–5 mg of each cannabinoid once or twice daily and titrates by 2.5–5 mg of each cannabinoid every 2 to 3 days until the patient reaches his/her goals or to a maximum THC dose of 40 mg/day. Conclusions In summary, using a modified Delphi process, expert consensus-based recommendations were developed on how to dose and administer medical cannabis for the treatment of patients with chronic pain.
Medical Cannabis in Oncology: a Valuable Unappreciated Remedy or an Undesirable Risk?

Mahmoud Abu-Amna,Talal Salti,Mona Khoury,Idan Cohen,Gil Bar-Sela

DOI: https://doi.org/10.1007/s11864-020-00811-2

2021-01-13

Current Treatment Options in Oncology

Abstract:The use of the cannabis plant by cancer patients has been rising significantly in the past few years worldwide, primarily driven by public demand. There is an obvious need for more reliable scientific data, pharmacology information, a better understanding of its mode of action, and available clinical evidence supporting its robust use. Physicians must complete a thorough medical assessment, screening for potential drugs, or treatment contraindications before allowing its consumption. In light of the growing popularity of cannabis usage, it is highly essential that, in the near future, the medical community will be able to provide practical recommendations and explicit guidelines, including doses, and that cannabinoid concentrations in the used products are defined regarding its prescription before any medical procedure involving its usage is authorized. Here, we review and describe the favorable outcomes demonstrating the benefits of cannabis as an adjunctive treatment to conventional medicines for chemotherapy-induced nausea, vomiting, and cancer-related pain (primarily refractory chronic or neuropathic pain). Although not yet substantial enough, the treatment of anorexia, insomnia, depression, and anxiety is also seemingly favorable. To date, reports regarding its anti-neoplastic effects or its potent immunosuppressive properties influencing response to immunotherapy are still very conflicting and controversial. Thus, with the current state of evidence, cannabis use is not advisable as initial treatment, as an adjunct or an advanced line of care. In the coming years, we expect that preclinical data and animal models will shift to the clinical arena, and more patients will be recruited for clinical trials, and their reports will advance the field. Thus, physicians should prescribe cannabis only if careful clarification and consideration is provided together with a follow-up response evaluation.

oncology
Potential role of cannabis in ameliorating observed racialized disparities in cancer pain management

Laurel P Gibson,Rebecca A Ferrer,Salimah H Meghani,Amanda M Acevedo

DOI: https://doi.org/10.1093/jnci/djae058

2024-03-12

Abstract:Abstract Cancer-related pain affects a large proportion of all patients with cancer yet remains inadequately managed, particularly among patients from certain racialized backgrounds. Recently, there has been increased research and clinical interest in the use of medical cannabis for cancer pain management, including its potential to ameliorate race-based disparities in cancer pain control. Although medical cannabis is not currently a US Food and Drug Administration–approved treatment option for cancer-related pain, many oncologists discuss and recommend its use with their patients, underscoring the need for researchers and clinicians to proactively identify barriers to cannabis for cancer pain management that may disproportionately affect patients from certain racial groups. In this commentary, we highlight challenges that patients from racialized backgrounds may face when incorporating cannabis into their palliative care regimens and discuss opportunities for researchers and clinicians to address these challenges should medical cannabis become a recommended treatment option for cancer pain management. In particular, we identify challenges at the structural (eg, lack of insurance coverage), clinician (eg, racialized stereotypes regarding addiction and pain), and individual (eg, internalized stigma) levels and emphasize the importance of multilevel approaches in combating these challenges as the evidence base regarding medical cannabis and its potential harms and therapeutic benefits continues to accumulate.

oncology
NP student knowledge and perceptions of medical marijuana

Clark Cassone,Patricia Rissmiller

DOI: https://doi.org/10.1097/01.NPR.0000000000000223

2024-09-01

Abstract:Objective: This study aimed to measure NP students' knowledge and perception of medical marijuana (MM) and determine whether they need additional education on the topic. Methods: A cross-sectional, descriptive study was implemented. NP students were asked to complete a survey that assessed their knowledge of MM, including adverse reactions and medical indications. Perceptions of recreational marijuana and MM were assessed through a 5-point Likert-scale questionnaire. Results: Of the 230 NP students who completed all or part of the questionnaire, 115 met inclusion criteria and were included in results. Most students (94%) felt that MM should be legalized in all US states. Likewise, 97% felt that MM education should be included in NP program curricula; however, only 30% reported receiving in-depth education on the topic. Participants were asked to identify, among 18 provided medical conditions, those which were approved indications for MM use; accurate response rate was low, though cancer, pain, cachexia, nausea/vomiting, posttraumatic stress disorder, and epilepsy were identified correctly as indications by more than half of participants. Previous MM use and religious affiliation had an impact on knowledge and perceptions of MM. Conclusion: With an increasing number of states legalizing MM, NP programs must evaluate their current curricula and integrate content that addresses the gap in knowledge of MM mechanism of action, indications, and adverse reactions.
'The wild west of medicine': A qualitative investigation of the factors influencing Australian health‐care practitioners' delivery of medicinal cannabis

Olivia Dobson,Michaela Barber,Myfanwy Graham,Adrian Carter,Michael Savic

DOI: https://doi.org/10.1111/dar.13847

2024-04-18

Drug and Alcohol Review

Abstract:Introduction Strong patient interest in the use of medicinal cannabis to treat various clinical indications has sparked global legislative changes. Practitioners are vital in implementing regulatory changes and facilitating patient access to medicinal cannabis, however, little is currently known about the factors influencing practitioners' uptake. Recent rapid increases in practitioner applications to prescribe medicinal cannabis in Australia provides a unique backdrop to examine the current factors influencing prescribing behaviours. This qualitative study examined Australian practitioners' perspectives on prescribing medicinal cannabis to provide a comprehensive exploration of the potential factors influencing uptake in clinical practice. Methods Seventeen semi‐structured interviews were conducted with Australian health‐care practitioners. Transcripts were analysed using the Framework approach to thematic analysis and cross‐mapped to appropriate domains of the Theoretical Domains Framework. Results We identified four themes related to the barriers and facilitators to prescribing medicinal cannabis: (i) clinical capabilities needed to prescribe; (ii) prescribing an unapproved therapeutic good; (iii) negative attitudes towards prescribers in the medical community; and (iv) divergent beliefs about clinical utility. Discussion and Conclusions Practitioners face multiple pervasive barriers to prescribing medicinal cannabis. Beliefs about clinical utility appear to be highly influential in shaping prescribing behaviours. Moreover, our findings suggest that a medicinal cannabis 'specialisation' has emerged within the Australian medical community. Findings demonstrate that a range of complex and multifaceted factors influence practitioners' medicinal cannabis prescribing behaviours. We highlight several considerations for policy and practice to support safe and appropriate patient access to medicinal cannabis in this emerging area of clinical practice.

substance abuse

More on mini-gastric bypass.

The Cannabis and Health Research Initiative will help integrate medicinal cannabis in healthcare

Patient–provider interactions about cannabis for therapeutic purposes vary as a function of provider type: A pilot study

State of the Science: Health Care Provider Communication of Cannabis Use Among Adults Living with Cancer

Planting the seeds for success: A qualitative study exploring primary healthcare providers’ perceptions about medical cannabis

Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues

Palliative Medicine Fellows’ Discussions, Perceptions, and Training Regarding Medical Cannabis

VA Providers' Perceptions of Cannabis Use Policies in a Legalized and Nonlegalized State

Early promising outcome following arthroscopic implantation of the subacromial balloon spacer for treating massive rotator cuff tear

Cannabis Use in Parkinson's Disease: Patient Access to Medical Cannabis and Physician Perspective on Product Safety

Analysis of State Cannabis Laws and Dispensary Staff Recommendations to Adults Purchasing Medical Cannabis

The evolving culture of medical cannabis in Canada for the management of chronic pain

Response competition effects insame-different judgments

Cannabis dispensary staff approaches to counseling on potential contraindications to cannabis use: insights from a national self-report survey

On Solving Lq-Penalized Regressions

Medical cannabis in schools: A qualitative study on the experiences of clinicians

Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process

Medical Cannabis in Oncology: a Valuable Unappreciated Remedy or an Undesirable Risk?

Potential role of cannabis in ameliorating observed racialized disparities in cancer pain management

NP student knowledge and perceptions of medical marijuana

'The wild west of medicine': A qualitative investigation of the factors influencing Australian health‐care practitioners' delivery of medicinal cannabis